A closer look at Delcath Systems' refuse-to-file letter

Last week's top story from FierceDrugDelivery discussed the FDA's refuse-to-file letter to New York-based Delcath Systems ($DCTH), which has sought the agency's approval of a liver-cancer treatment that uses catheters to isolate the organ and saturate it with chemotherapy. Just after publishing, I noticed that TheStreet.com's Adam Feuerstein took a deeper look at the agency's concerns regarding how Delcath characterized safety data about the long-approved chemotherapy drug, melphalan, which the firm delivers with its catheter-based system to treat skin cancer that spreads to the liver. "The safety question was the linchpin behind the refuse-to-file letter," Eamonn Hobbs, the company's CEO, told TheStreet. "FDA decided it wanted to see our melphalan safety data stand on its own." Story

Suggested Articles

The new digital Abilify is a breakthrough for Proteus Digital Health and its patient-tracking products, but not so much for Abilify's maker, Otsuka.

Adamis Pharmaceuticals' EpiPen contender Symjepi, which was rejected last year before the EpiPen havoc, won approval from the FDA.

Researchers in the U.K. have developed a technique to better predict results in liver cancer when drug-laden polymer beads are used to deliver medicines.